All In Biotech

Drug Trial Radar · NCT05961098

A Study of RBD1016 in CHB Participants

A Phase II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of RBD1016 Injection in Participants With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 11, 2023

Primary completion

Apr 29, 2025

Study completion Oct 15, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, randomized, double-blind, placebo-controlled clinical study to assess the safety, efficacy, PK and immunogenicity of RBD1016 injection on NAs background treatment in CHB participants.

Conditions

  • Chronic Hepatitis b

Interventions

  • RBD1016Drug

    RBD1016 with NAs background treatment will be explored.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety: number and percentage of AEsTime frame: 24 weeks
  2. efficacy: the maximum decline of HBsAg levelTime frame: 24 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, China

  • Queen Mary Hospital

    Hong Kong, China

  • Karolinska University Hospital

    Stockholm, Stockholm County, Sweden

  • Clinical Trial Consultants AB

    Uppsala, Uppsala County, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.